Shares of automation software company UiPath (NYSE: PATH) rallied 18.3% in December, according to data from S&P Global Market ...
However, Palantir's huge gains have left the stock at a huge valuation; it's trading at a forward price-to-sales (P/S) ...
UiPathは6月19日、製品アップデートに関する記者説明会を開催した。 同社カントリーマネージャーの南哲夫氏は、「我々はAI-Powered Business Automation Platformを推進している」と強調する。同社はRPAツールの印象が強いが、AIを搭載した自動化に強みがあるという。
UiPath (PATH) has been in focus after CEO Daniel Dines disclosed share sales under a pre arranged trading plan at the same time the company entered the S&P MidCap 400, which drew extra attention to ...
CEO and Chairman, Dines Daniel, sold shares worth around $1.5 million earlier in the week. ・He sold 90,000 shares of the ...
Model Context Protocol-based agentic integration allows for faster, more accurate access and usage of data and information to reduce errors and elevate productivity ...
ロボット処理による自動化ソフトウエア開発のUiPath <PATH> が上昇。S&P中型株400指数の算出銘柄に採用される。1月2日の取引開始前から。金融サービスのシノバス <SNV> が除外される。
Investor's Business Daily on MSN

UiPath sees composite rating move up to 96

UiPath PATH saw its IBD SmartSelect Composite Rating rise to 96 Wednesday, up from 94 the day before. Please watch the video at Investors.com - Stock Market Exposure: How To Make Incremental Portfolio ...
Figma went public at $33 last July and currently trades at approximately $37. UiPath went public at $56 in April 2021, but it ...
If you are wondering whether UiPath's share price reflects its true worth or leaves some room on the table, you are in the right place. UiPath's stock closed at US$15.88, with a 5.7% decline over the ...
■ 製造業で進む自動化と、AIエージェント活用への期待 ...
Testing an AI agent for donor tissue screening at Evergen surfaces more than technical performance questions. The project ...